My oncologist told me today that I could now take Zometa every 3 months instead of monthly. This was based on information from the ASCO 2015 meeting, he said. I like this, considering what a bad thing osteonecrosis of the jaw (ONJ) is.
Anyone heard about this or have a link with more info?
M.
Forums
5 posts
• Page 1 of 1
-
RadiantTiger - Name: Radiant Tiger
- Who do you know with myeloma?: Myself, my deceased uncle
- When were you/they diagnosed?: Feb 2015
- Age at diagnosis: 54
Re: Less frequent Zometa dosing - ASCO 2015 abstract?
Your onc is probably referring to this abstract:
AL Himelstein et al, "CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer," ASCO 2015 abstract 9501 (abstract)
Abstract:
Background: Zoledronic acid (ZA) given monthly for 24 months (mo) reduces bone pain and skeletal-related events (SRE) in patients (pts) with bone metastases. We tested whether ZA every 3 mo would be non-inferior to monthly for 24 mo, with less toxicity, in a randomized trial in 1822 pts: breast (n = 833), prostate (n = 674), myeloma (n = 270), and other (n = 45).
Methods: SRE were defined as radiation therapy (RT) to bone, fractures, spinal cord compression or surgery to bone within 24 mo. ZA doses were adjusted for creatinine clearance. The primary endpoint was the proportion of pts in each group who had ≥ 1 SRE; secondary endpoints included skeletal morbidity rates, performance status, pain using the Brief Pain Inventory, and incidences of jaw osteonecrosis and renal dysfunction. The trial design was non-inferiority (NI) with stratification and pre-planned analyses by disease. The NI margin was 7% absolute difference. With 1,230 pts (planned sample size 1758 with 30% allowance for inevaluable pts), the power was > 82% when the NI margin was < 0 using a 1-sided test at a 5% significance level.
Results: Between May 1, 2009 and April 13, 2012, 1822 pts were randomized. Baseline characteristics of the 2 groups were comparable. Dose delays were more common with ZA monthly. The 2-year cumulative incidences of SRE and selected toxicities are presented in the Table. The proportions of SRE were 29.5% vs 28.6% (95% CI for margin: -3.3% to 5.1%, Cochran-Maentel-Hanzel p = 0.79) for monthly and every 3 mo, respectively.
Conclusions: ZA administered every 3 mo is non-inferior to ZA administered monthly for 24 mo in breast cancer, prostate cancer and multiple myeloma. Bone turnover markers in a subset of pts and a cost analysis will be presented. Clinical trial information: NCT00869206.
AL Himelstein et al, "CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer," ASCO 2015 abstract 9501 (abstract)
Abstract:
Background: Zoledronic acid (ZA) given monthly for 24 months (mo) reduces bone pain and skeletal-related events (SRE) in patients (pts) with bone metastases. We tested whether ZA every 3 mo would be non-inferior to monthly for 24 mo, with less toxicity, in a randomized trial in 1822 pts: breast (n = 833), prostate (n = 674), myeloma (n = 270), and other (n = 45).
Methods: SRE were defined as radiation therapy (RT) to bone, fractures, spinal cord compression or surgery to bone within 24 mo. ZA doses were adjusted for creatinine clearance. The primary endpoint was the proportion of pts in each group who had ≥ 1 SRE; secondary endpoints included skeletal morbidity rates, performance status, pain using the Brief Pain Inventory, and incidences of jaw osteonecrosis and renal dysfunction. The trial design was non-inferiority (NI) with stratification and pre-planned analyses by disease. The NI margin was 7% absolute difference. With 1,230 pts (planned sample size 1758 with 30% allowance for inevaluable pts), the power was > 82% when the NI margin was < 0 using a 1-sided test at a 5% significance level.
Results: Between May 1, 2009 and April 13, 2012, 1822 pts were randomized. Baseline characteristics of the 2 groups were comparable. Dose delays were more common with ZA monthly. The 2-year cumulative incidences of SRE and selected toxicities are presented in the Table. The proportions of SRE were 29.5% vs 28.6% (95% CI for margin: -3.3% to 5.1%, Cochran-Maentel-Hanzel p = 0.79) for monthly and every 3 mo, respectively.
Conclusions: ZA administered every 3 mo is non-inferior to ZA administered monthly for 24 mo in breast cancer, prostate cancer and multiple myeloma. Bone turnover markers in a subset of pts and a cost analysis will be presented. Clinical trial information: NCT00869206.
- ASCOTable.png (19.15 KiB) Viewed 956 times
-
Multibilly - Name: Multibilly
- Who do you know with myeloma?: Me
- When were you/they diagnosed?: Smoldering, Nov, 2012
Re: Less frequent Zometa dosing - ASCO 2015 abstract?
The UK Myeloma XI trial that I am on reduces from monthly to quarterly the intervals for Zometa after 2 years. Allegedly, the system is "saturated" by then, whatever that means!
Always pleasing to shed a treatment.
Regards,
Ray
Always pleasing to shed a treatment.
Regards,
Ray
-
Ray Ranns
Re: Less frequent Zometa dosing - ASCO 2015 abstract?
Multibilly, Have you found any other articles or discussions on this frequency of Zometa infusion issue raised by Radiant Tiger?
Re: Less frequent Zometa dosing - ASCO 2015 abstract?
Originally I was supposed to get Zometa every month for a couple years before decreasing the interval. But now after my stem cell transplant 4 months ago, I got my dose and my doc says every three is just as good as monthly.
Thank goodness! As I hate the 3 day "flu" symptoms I get with it.
Thank goodness! As I hate the 3 day "flu" symptoms I get with it.
-
heddleandhook - Name: heddleandhook
- Who do you know with myeloma?: self
- When were you/they diagnosed?: Jan 2015
- Age at diagnosis: 68
5 posts
• Page 1 of 1
Return to Treatments & Side Effects